Slide 1: 9M 2022 Results
9M 2022 RESULTS October 27, 2022
Slide 2: Disclaimer
Disclaimer In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“DiaSorin” or the “Co
Slide 3: Forward-looking statements
Forward-looking statements This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaS
Slide 4: Financial Highlights
Financial Highlights* Change(**) Change Data in €/mln Q3’22 9M’22 @ current @ CER @ current @ CER Revenues 327 -4.8% -13.8% 1,012 +17.9% +9.6% Immunodiagnostics ex-COVID 172 +9.5% +2.5% 504 +9.8% +4.4% Molecular Diagnostics ex-COVID 54 +23.4% +7.1% 151 +89.5% +70.1% Licensed Technologies 49 +11.2% -
Slide 5: Immunodiagnostics and Molecular Diagnostics 9M 2022 key facts
9M 2022 key facts Product Development Business Development • New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use • Appointment of Angelo Rago, a senior executive with a 30+ years experience in Only) for the detection and discrimination of mutations associated with MedTech global companies,
Slide 6: Managerial outlook on Q3 2022 and 9M 2022 revenues
Managerial outlook on Q3(*) 2022 and 9M 2022 revenues Total Q3(*) Group revenues (data in €/mln) Total 9M Group revenues (data in €/mln) Data @CER Data @CUR Data @CER Data @CUR -14% -5% +10% +18% 941 1,012 343 343 327 859 859 296 187 +39% 201 +12% 52 +29% 98 +2% 46 98 276 276 275 583 754 583 811 250
Slide 7: Q3 2022 and 9M 2022 revenues growth by geography and technology
Q3(*) 2022 and 9M 2022 revenues growth by geography and technology Q3’22 vs. 9M’22 vs. Q3’22 vs. 9M’22 vs. BY GEOGRAPHY (change @ CER) BY TECHNOLOGY Q3’21 9M’21 Q3’21 9M’21 EUROPE DIRECT EX-COVID • Positive performance of Immunodiagnostics ex-COVID sales (Latent TB, reported +9.5% +9.8% IMMUNODIAGNO
Slide 8: 9M 2022 revenues: managerial outlook
9M 2022 revenues: managerial outlook BY GEOGRAPHY BY TECHNOLOGY 9M’21 North America Direct Rest of the World 9M’21 15.6% COVID 25.2% 32.1% Immunodiagnostics ex-COVID 53.4% Europe Direct Licensed Technologies COVID 27.1% 5.2% 32.1% Molecular Diagnostics ex-COVID 9.3% North America Direct 39.0% COVID
Slide 9: Q3 2022 and 9M 2022 profitability profile
Q3(*) 2022 and 9M 2022 profitability profile (data in €/mln @ current exchange rates) 40.5% 37.4% 327 343 Adjusted EBITDA(**) reflects: 139 122 • Growth in revenues • Decrease in profitability due to: Q3'21 (*) Q3'22 (*) o lower COVID sales o inclusion of Luminex in the scope of consolidation, resul
Slide 10: FY 2022 Guidance revised upwards
FY 2022 Guidance revised upwards NEW FY 2022 GUIDANCE at 2021 CER: ▪ REVENUES: between +2% and 3% approx. vs. FY’21, with COVID revenues at about € 225 million and ex- COVID revenues growing at approx. 22% ▪ ADJUSTED EBITDA* MARGIN: between 38% and 39% approx. * With reference to the Adjusted EBITDA
Slide 11: Financial schemes
Financial schemes ee *
Slide 12: Income Statement
Income Statement 9M Q3 (Amounts in million of euros) 2021 2022 2021 2022 Net Revenues 858.9 1,012.3 343.5 326.8 Cost of sales (279.0) (341.7) (118.9) (105.8) Gross profit 579.9 670.6 224.5 221.0 67.5% 66.2% 65.4% 67.6% Sales and marketing expenses (133.1) (214.8) (58.4) (72.9) Research and developme
Slide 13: Adjusted Income Statement
Adjusted(*) Income Statement 9M Q3 (Amounts in million of euros) 2021 2022 2021 2022 Net Revenues 858.9 1,012.3 343.5 326.8 Cost of sales (279.0) (340.0) (118.9) (105.8) Gross profit 579.9 672.2 224.5 221.1 67.5% 66.4% 65.4% 67.6% Sales and marketing expenses (133.1) (185.7) (58.4) (62.7) Research a
Slide 14: Reconciliation to consolidated financial statements
Reconciliation to consolidated financial statements Data in €/mln Gross Margin EBITDA2 EBIT Fiscal impact Net Profit IFRS Financial Statements Measures 579.9 367.6 314.1 n.a. 229.3 % on Revenues 67.5% 42.8% 36.6% 0.0% 26.7% 9M 2021 Adjustments One-off” Costs related to the acquisition of Luminex - 1
Slide 15: Balance Sheet
Balance Sheet (Amounts in million of euros) 12/31/2021 09/30/2022 Change Goodwill and intangibles assets 1,943.4 2,208.3 +265.0 Property, plant and equipment 276.2 294.0 +17.9 Other non-current assets 42.6 49.0 +6.4 Net working capital 361.9 396.1 +34.2 Other non-current liabilities (270.2) (303.4)
Slide 16: Cash flow statement
Cash flow statement 9 months Q3 (Amounts in million of euros) 2021 2022 2021 2022 Cash and cash equivalents at the beginning of the period 339.9 403.0 896.8 382.4 Cash provided by operating activities 301.1 307.3 127.5 127.2 Cash used in investing activities (83.3) (70.4) (33.7) (18.5) Cash provided
Slide 17: DiaSorin
DiaSorin